Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint

Larimar Therapeutics, Inc.

2025-Q1 EPS reported -$0.46

Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.
Cash, equivalents and marketable securities $157.5M as of March 31, 2025; runway into Q2 2026.
FDA agreed to consider skin FXN concentration as reasonably likely surrogate endpoint for accelerated approval.
BLA submission planned by year-end 2025; global Phase 3 study to begin mid-2025 with U.S. and international sites.
Adolescent PK run-in dosing completed; 50 mg OLE and adolescent data expected in September 2025 program update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.